English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The BD MAX™ Enteric Bacterial Panel (BDM-EBP) is designed and FDA-cleared to detect  Salmonella, Shigella, Campylobacter,  and Shiga toxin genes  stx1/2  from stool samples. However, rectal swabs, which are not FDA-cleared for clinical testing with the BDM-EBP, are common specimens received from pediatric patients for enteric pathogen testing. The purpose of this study was to evaluate the ability of the BDM-EBP to detect stool pathogens from rectal swabs.    Methods  Routine cultures, Shiga toxin testing, and molecular testing with BDM-EBP were performed on 272 sequential rectal swabs collected from August 2015 to December 2015. Discrepant test results were resolved using Verigene® Enteric Pathogens Nucleic Acid Test (EP). 36 challenge samples (13  Salmonella  spp., 3  Shigella  spp., 10  Campylobacter  spp., and 10 Shiga toxin positive  Escherichia coli ) were tested using reference strains (American Type Culture Collection) and previous patient isolates diluted to10 3 -10 4  cfu/ml in saline then added to Sample Buffer Tube (SBT) with negative stool matrix delivered via a swab. Limit of detection testing was performed by serial 10 fold dilutions in saline then added to SBT with negative stool matrix provided via a swab.    Results  A total of 272 rectal swab specimens were evaluated and 89 were positive by culture and/or MAX EBP. All discrepant results were BDM-EBP positive and culture negative. 21 of 31 (68%) of the apparent false positive BDM-EBP discrepant results resolved as positive with Nanosphere’s Verigene® EP. After resolution of the discordant results, the Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) are as follows for each target:  Salmonella  ( n  = 4) 100%, PPA and 100%, NPA;  Shigella  ( n  = 79) 100%, PPA and 95.3%, NPA;  Campylobacter  ( n  = 4) 100%, PPA and 99.6%, NPA; and Shiga toxin producing organisms ( n  = 2) 100%, PPA and 100%, NPA. 8.8% of the patient samples did not initially yield a result on the BDM-System. Upon repeat, half of the problematic samples resolved, and 4.4% of the total specimen tested did not yield a result. All organisms in the challenge samples were detected. Limits of detection for BDM-EBP testing of rectal swabs were as follows (in cfu/ml in SBT):  Salmonella -1.44 × 10 2 ;  Shigella -5.10 × 10 0 ;  Campylobacter -1.51 × 10 1 ; and Shiga Toxin-1.13 ×10 3 .    Conclusion  Rectal swabs are acceptable samples for detecting  Salmonella ,  Shigella ,  Campylobacter , and Shiga toxin using BDM-EBP.

Utilizing BD MAX™ Enteric Bacterial Panel to Detect Stool Pathogens from Rectal Swabs